Carisma is a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on chimeric antigen receptor macrophages
PHILADELPHIA, March 5, 2019 /PRNewswire/ -- Carisma Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on chimeric antigen receptor macrophages, today announced that the Company’s management will present at three upcoming investor and industry conferences:
The Alliance for Regenerative Medicine Cell & Gene Investment Day is filmed and livestreamed from the meeting website at http://arminvestorday.com/webcast/. About Carisma Therapeutics Inc. Carisma Therapeutics Inc. is biopharmaceutical company bringing the power of adoptive cellular immunotherapy to solid tumor patients through a differentiated platform using chimeric antigen receptor macrophages. Carisma Therapeutics is headquartered in Philadelphia, PA. For more information, please see the Company’s website at https://carismatx.com/. Media Contact: Deirdre Purdy for Carisma Therapeutics
SOURCE Carisma Therapeutics Inc. |